Shots:
- Dizal has completed pts enrollment in P-III (WU-KONG28) trial of sunvozertinib as a 1L treatment of NSCLC harboring EGFR exon 20 insertion mutations (exon20ins); NDA under the US FDA’s priority review (PDUFA: Jul 7, 2025)
- Trial assessed sunvozertinib vs Pt-based doublet CTs in treatment-naïve NSCLC pts with EGFR exon20ins across 16 countries & regions in Asia, EU, North & South America
- At ESMO 2023, Dizal reported that sunvozertinib achieved a 100% reduction of target lesions, cORR of 78.6%, & mPFS of 12.4mos. in 1L advanced or metastatic NSCLC pts with EGFR exon20ins
Ref: Prnewswire | Image: Dizal| Press Release
Related News:- Neuspera Medical’s Integrated Sacral Neuromodulation System Secures the US FDA Approval for Urinary Urge Incontinence
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
